VAERS reports by lot

GSK Varicella/Shingles lot GL2HR: VAERS reports

65 VAERS reports list lot GL2HR as a GSK Varicella/Shingles vaccine, received between 2018-12-17 and 2021-01-13. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
65
Reports
5%
Marked serious
0
With a death outcome
14
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
General / Systemic (non-local)7832%
Injection-site / Local reaction4719%
Neurological2912%
Dermatological (non-injection-site)2611%
Musculoskeletal208%
Gastrointestinal135%
Respiratory94%
Allergic / Anaphylactic83%
Cardiac / Cardiovascular73%
Psychiatric / Neuropsychiatric73%
Autoimmune / Immune-mediated31%

Where reports came from

U.S. state of the reporter, where given (top 12).

California8
New York7
Minnesota6
Pennsylvania4
Ohio3
New Jersey3
Texas3
Washington3
Georgia3
Utah2
Tennessee2
Virginia2

Reports by month received

2018-126
2019-0120
2019-0213
2019-038
2019-045
2019-051
2019-063
2019-073
2019-081
2019-091
2019-101
2019-111
2020-021
2021-011

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.